MediWound (NASDAQ:MDWD) Issues Earnings Results, Beats Expectations By $0.57 EPS

MediWound (NASDAQ:MDWD) issued its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.81) by $0.57, Zacks reports. MediWound had a negative return on equity of 96.71% and a negative net margin of 142.18%.

MediWound Trading Down 0.8%

Shares of MDWD stock opened at $17.71 on Thursday. MediWound has a 1 year low of $14.14 and a 1 year high of $22.50. The firm’s 50 day moving average is $18.08 and its 200-day moving average is $18.85. The firm has a market capitalization of $196.40 million, a price-to-earnings ratio of -6.67 and a beta of 0.22.

Analyst Ratings Changes

A number of research analysts recently commented on the company. Weiss Ratings restated a “sell (d-)” rating on shares of MediWound in a research note on Wednesday, October 8th. Zacks Research upgraded shares of MediWound from a “strong sell” rating to a “hold” rating in a research report on Tuesday, November 11th. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $32.25.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of MDWD. Millennium Management LLC lifted its stake in shares of MediWound by 355.6% during the third quarter. Millennium Management LLC now owns 175,383 shares of the biopharmaceutical company’s stock valued at $3,160,000 after acquiring an additional 136,884 shares during the period. UBS Group AG raised its holdings in MediWound by 15.3% during the 3rd quarter. UBS Group AG now owns 76,301 shares of the biopharmaceutical company’s stock worth $1,375,000 after purchasing an additional 10,102 shares during the last quarter. Sargent Investment Group LLC lifted its position in MediWound by 11.1% during the 3rd quarter. Sargent Investment Group LLC now owns 59,926 shares of the biopharmaceutical company’s stock valued at $1,080,000 after purchasing an additional 6,000 shares during the period. The Manufacturers Life Insurance Company grew its position in shares of MediWound by 104.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 26,062 shares of the biopharmaceutical company’s stock worth $505,000 after buying an additional 13,312 shares during the period. Finally, Marshall Wace LLP bought a new stake in shares of MediWound during the second quarter worth approximately $317,000. 46.83% of the stock is currently owned by institutional investors.

MediWound Company Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.